HYDRALAZINE? ESSENTIAL OR HAS A POTENTIAL FOR COMPLICATIONS IN DERMATOLOGY

Autor: Neelima Ravipati, Satish Kumar S, Chanabasappa Mendagudli
Rok vydání: 2015
Předmět:
Zdroj: Journal of Evidence Based Medicine and Healthcare, Vol 2, Iss 7, Pp 783-788 (2015)
ISSN: 2349-2570
2349-2562
Popis: BACKGROUND : Hydralazine is a drug which is vasodilator, it lowers blood pressure and allows blood to flow more easily in veins and arteries. Hydralazine is used to treat hypertension. OBJECTIVES : The purpose of this prospective study is to determine role of – Hydralazine in dermatological complications. METHODS : In this descriptive, prospective, observational, cross sectional study, all patients who presented to the department of dermatology during this study period of 12 months from January 2010 - December 2010 in . were included. RESULTS : Total number of males in the present study was 19(74%), females in the study was 6(26%). Mean age was 55.28±15.74 (SD) years, number of patients in the age group 31 - 40 years was 3(12%), 41 - 50 years was 5(20%), 51 - 60 years was 7(28%), number of patients in 61 - 70 years was 4(16%), number of patients in the age group 71 - 80 years was 4(16%), number of patients in the age group 71 - 80 years was 2(8%). Maximum number of patients was in their middle age between 41 - 60 years. Flushing was seen in 8(32%) patients, Urticarial rashes were seen in 10(40%) patients, Lupus - like syndrome was seen in 5(20%) patients, Hypersensitivity reactions was seen in 5(20%) patients, ANA - positivity was seen in 5(20%) patients, out of all the dermatological manifestations Urticarial rashes were seen in maximum number of patients i . e ., in 10(40%) patients. Lupus - like syndrome was seen in 5(20%) patients all of whom belonged to the age group 31 - 60 years. Flushing was seen in 6 (31.57%) patients in males, Urticarial rashes were seen in 8(42.10%) male, lupus like syndrome was seen in 5(26.31%) males, hypersensitivity was seen in 4(21.05%) males and ANA positivity was seen in 5(26.31%) males. Flushing was seen in 2(33.33%) patients in females, Urticarial rashes were seen in 2(33.33%) females, hypersensitivity was seen in 1(16.66%) females and ANA positivity & lupus like syndrome was not seen in females. P value of all symptoms being insignificant. CONCLUSION : There is significant percentage of patients who report with dermatological manifestations with hydralazine in first 6months after initiation as an add on drug
Databáze: OpenAIRE
Externí odkaz: